News

BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery

BenevolentAI will be proudly sponsoring NeurIPS again this year. Here are the details of our activities during the week:

Expo day: 6th December

How we leverage machine learning and AI to develop life-changing medicines - a case study with COVID-19.

The model for drug discovery and development is failing patients. It is expensive and high risk, with long research and development cycles. In this talk, we will discuss the peculiarities of machine learning across drug discovery, from the processing of scientific literature, to knowledge completion, target identification to precision medicine, to chemistry optimisation, each leveraging domain expert knowledge and state-of-the-art research and we will conclude our talk with a real example which will showcase the application of our technology and scientific expertise to repurpose existing drugs, as a potential treatment for COVID-19. 

Expo Schedule →

Meetup: 8th December

Application of Machine Learning to Drug Discovery Meetup

Why is drug discovery so complex? How can ML help to solve these scientific challenges? What does an ML applied drug discovery model look like? What skills are useful to the industry? If you are asking yourself some of these questions, then this meetup is for you.

Save your spot →


Our Research at NeurIPS

Learning Meaningful Representations of Life workshop:

Our AI Science Intern, Constantin Schneider, will present his paper on ‘Auxiliary task evaluations to learn meaningful representations from electronic health records', co-authored by BenevolentAI's Senior Machine Learning Researcher, Hamish Tomlinson, at the Learning Meaningful Representations of Life workshop.

Authors: Hamish Tomlinson, Constantin Schneider

----

Machine Learning for Molecules Workshop

Our team will be presenting their paper on 'Molecular representation learning with language models and domain-relevant auxiliary tasks' at the Machine Learning for Molecules Workshop.

Authors: Fabian et al. (2020)



Network with our team: join us on Hopin

While you're at NeurIPS, connect with our team virtually via the Hopin platform. Connect with our team at networking sessions to ask any questions you may have, and/or join our careers with impact meetup to learn more about what we do and how we work. The full programme will be coming soon. As we have limited space, we advise you to book your spot now.

Save your spot → Neurips Expo → Talent Pool →
More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021